Pharmacyclics Company Profile (NASDAQ:PCYC)

About Pharmacyclics

Pharmacyclics logoPharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: PCYC
  • CUSIP: 71693310
Key Metrics:
  • Previous Close: $257.10
  • 50 Day Moving Average: $256.91
  • 200 Day Moving Average: $195.29
  • 52-Week Range: $85.50 - $261.68
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 48.97
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Pharmacyclics:

Analyst Ratings

Consensus Ratings for Pharmacyclics (NASDAQ:PCYC) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Pharmacyclics (NASDAQ:PCYC)
DateFirmActionRatingPrice TargetDetails
5/29/2015BTIG ResearchReiterated RatingNeutralView Rating Details
4/20/2015BMO Capital MarketsReiterated RatingPositiveView Rating Details
3/6/2015Credit Suisse GroupReiterated RatingNeutralView Rating Details
3/6/2015Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
3/6/2015WallachBeth CapitalBoost Price TargetHold$222.00 -> $261.00View Rating Details
3/5/2015Piper Jaffray CompaniesSet Price TargetHold$184.00View Rating Details
3/5/2015NomuraDowngradeBuy -> Neutral$196.00 -> $261.25View Rating Details
3/5/2015Wells Fargo & CompanyDowngradeOutperform -> Market Perform$261.25View Rating Details
3/5/2015Royal Bank Of CanadaBoost Price TargetSector Perform$145.00 -> $261.00View Rating Details
3/3/2015WedbushDowngradeOutperform -> Neutral$225.00 -> $234.00View Rating Details
2/27/2015Goldman Sachs Group, Inc. (The)DowngradeHold$184.00View Rating Details
2/26/2015Robert W. BairdBoost Price Target$240.00View Rating Details
2/25/2015Deutsche Bank AGDowngradeBuy -> Hold$235.00View Rating Details
(Data available from 2/21/2015 forward)


Earnings History for Pharmacyclics (NASDAQ:PCYC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2015Q115$0.11$0.13$226.27 million$206.00 millionViewN/AView Earnings Details
2/18/2015Q414$0.76$0.96$267.50 million$290.00 millionViewN/AView Earnings Details
11/4/2014Q314$0.37$0.69$201.50 million$207.10 millionViewN/AView Earnings Details
7/31/2014Q214($0.23)($0.26)$95.88 million$113.00 millionViewN/AView Earnings Details
5/2/2014Q114$0.17$0.40$105.38 million$119.40 millionViewN/AView Earnings Details
2/20/2014Q413$0.67$0.95$85.69 million$123.60 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.07)$0.26$52.00 million$54.70 millionViewN/AView Earnings Details
5/1/2013Q3 2013($0.03)($0.40)$2.84 millionViewN/AView Earnings Details
2/14/2013Q2 2013$0.29$0.62$45.74 million$57.96 millionViewN/AView Earnings Details
11/5/2012Q113$0.75$1.14$87.64 million$102.70 millionViewN/AView Earnings Details
9/5/2012Q412($0.27)($0.22)$3.49 million$2.10 millionViewN/AView Earnings Details
5/10/2012($0.20)($0.14)ViewN/AView Earnings Details
2/9/2012($0.18)$0.82ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pharmacyclics (NASDAQ:PCYC)
Current Year EPS Consensus Estimate: $0.73 EPS
Next Year EPS Consensus Estimate: $5.25 EPS


Dividend History for Pharmacyclics (NASDAQ:PCYC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Pharmacyclics (NASDAQ:PCYC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/13/2015Manmeet Singh SoniCFOSell27,514$254.24$6,995,159.36View SEC Filing  
3/12/2015Heow TanInsiderSell1,000$254.51$254,510.00View SEC Filing  
11/12/2014Maky ZanganehCOOSell30,482$134.69$4,105,620.58View SEC Filing  
11/10/2014Maky ZanganehCOOSell23,000$133.83$3,078,090.00View SEC Filing  
11/10/2014Richard B LoveGeneral CounselSell1,500$133.87$200,805.00View SEC Filing  
11/7/2014Maky ZanganehCOOSell1,551$135.01$209,400.51View SEC Filing  
11/7/2014Maria FardisInsiderSell5,000$134.50$672,500.00View SEC Filing  
9/4/2014Maky ZanganehCOOSell12,000$121.75$1,461,000.00View SEC Filing  
8/27/2014Richard B LoveGeneral CounselSell1,500$124.00$186,000.00View SEC Filing  
8/13/2014Heow TanInsiderSell10,000$123.58$1,235,800.00View SEC Filing  
8/7/2014Jesse McgreivyInsiderSell34,062$120.92$4,118,777.04View SEC Filing  
3/5/2014Boultbee Paula SjovallEVPSell20,000$138.22$2,764,400.00View SEC Filing  
3/5/2014Gregory HemmiVPSell15,000$140.00$2,100,000.00View SEC Filing  
3/5/2014Jesse McgreivyInsiderSell6,563$139.66$916,588.58View SEC Filing  
3/4/2014Betty ChangVPSell17,500$137.97$2,414,475.00View SEC Filing  
2/27/2014Den Broek Richard VanDirectorSell78,835$146.63$11,559,576.05View SEC Filing  
12/19/2013Heow TanInsiderSell5,000$100.87$504,350.00View SEC Filing  
12/18/2013Gregory HemmiVPSell20,000$100.52$2,010,400.00View SEC Filing  
12/16/2013Rainer ErdtmannVPSell54,000$107.77$5,819,580.00View SEC Filing  
6/6/2013Scott T ShearerVPSell18,750$85.17$1,596,937.50View SEC Filing  
5/31/2013Heow TanInsiderSell5,237$91.84$480,966.08View SEC Filing  
5/31/2013Jesse McgreivyVPSell14,479$91.13$1,319,471.27View SEC Filing  
2/5/2013David J LouryInsiderSell20,000$70.58$1,411,600.00View SEC Filing  
12/28/2012Den Broek Richard VanDirectorSell30,285$57.99$1,756,227.15View SEC Filing  
12/27/2012Gregory HemmiVPSell13,000$59.20$769,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Pharmacyclics (NASDAQ:PCYC)
News IconGlobal Epigenetics Drugs Market Analysis: Drug Type, Mechanism of Action, Growth Trends and Forecast to 2020, New Findings by iHealthcareAnalyst, Inc. (NASDAQ:PCYC) - February 18 at 6:17 PM
News IconBrokers Add To Their Ratings On Pharmacyclics, Inc. (NASDAQ:PCYC) - NewsDen (NASDAQ:PCYC) - February 18 at 11:40 AM logoFormer Pharmacyclics execs take 17% stake in Pulse Bio; shares up 33% (NASDAQ:PCYC) - February 10 at 9:47 AM
News IconDrugs & Targets FDA approves first drug for marginal zone lymphoma - The Cancer Letter Publications (NASDAQ:PCYC) - January 28 at 7:16 PM
News IconPharmacyclics, Inc. (NASDAQ:PCYC) Updated Broker Ratings - NewsDen (NASDAQ:PCYC) - January 28 at 7:16 PM
News IconJohnson and Johnson seals $30b Actelion deal in push for rare disease (NASDAQ:PCYC) - January 27 at 5:36 AM
News IconJ&J seals $30bn Actelion deal (NASDAQ:PCYC) - January 27 at 5:36 AM
News IconJohnson & Johnson to buy Actelion for $30 b (NASDAQ:PCYC) - January 27 at 5:36 AM logoAbbvie (ABBV) Imbruvica Approved in Lymphoma Indication (NASDAQ:PCYC) - January 20 at 7:59 PM
News IconFDA Approves Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma (NASDAQ:PCYC) - January 20 at 4:52 AM logoAbbVie (ABBV) Announces FDA Approval for IMBRUVICA to Treat Specifically Indicated for R/R MZL - (NASDAQ:PCYC) - January 19 at 11:50 PM
News IconNew Ibrutinib (IMBRUVICA®) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma ... - Military Technologies (NASDAQ:PCYC) - January 18 at 12:31 AM
News IconNew Ibrutinib (IMBRUVICA®) Phase 2 Data Demonstrate Promise in ... - Military Technologies (NASDAQ:PCYC) - January 14 at 7:14 PM
News IconImbruvica shows benefit in chronic GVHD study (NASDAQ:PCYC) - December 7 at 7:04 PM logoAbbVie (ABBV) Announces Presentation of Positive IMBRUVICA Phase 2 Data in cGVHD (NASDAQ:PCYC) - December 7 at 7:04 PM
News IconNew Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond to Treatment with... (NASDAQ:PCYC) - December 7 at 7:04 PM logoLate-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients … (NASDAQ:PCYC) - December 6 at 11:54 PM logoAbbVie (ABBV) Updates on Five-Year IMBRUVICA Data in CLL/SLL; Strong CR/PR Results Noted - (NASDAQ:PCYC) - December 6 at 6:52 PM logoAbbVie (ABBV) Announces Presentation of Positive IMBRUVICA Phase 2 Data in cGVHD - (NASDAQ:PCYC) - December 6 at 6:52 PM logoIMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and - PR Newswire (press release) (NASDAQ:PCYC) - December 5 at 9:48 AM logoData at ASH 2016 Show Strong, Lasting Efficacy of Imbruvica® (ibrutinib) Through Five Years of Treatment for ... - Business Wire (press release) (NASDAQ:PCYC) - December 5 at 9:48 AM logoJanssen Announces Follow-up Data on IMBRUVICA Phase 1b/2 as ... - (NASDAQ:PCYC) - December 5 at 9:48 AM
News IconPharmacyclics, Inc. PCYC Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:PCYC) - November 21 at 12:03 PM logoGilead Sciences Closes Above Its Downward Channel, Are Future Gains To Follow? - Seeking Alpha (NASDAQ:PCYC) - November 15 at 10:29 AM
News IconWhy ACADIA Pharmaceuticals Inc (ACAD) Stock Loss Will Reverse With Nuplazid Sales, Eventually! - BNL Finance (press release) (registration) (blog) (NASDAQ:PCYC) - October 25 at 6:46 PM
News IconACADIA Pharmaceuticals Inc: ACAD Stock Owners Must See This Chart! - BNL Finance (press release) (registration) (blog) (NASDAQ:PCYC) - October 14 at 6:28 PM logoAbbVie : Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma (NASDAQ:PCYC) - September 27 at 6:34 PM
News IconActive Eye Catching Stocks- AbbVie (NYSE:ABBV), Pain Therapeutics (NASDAQ:PTIE), Lands' End (NASDAQ:LE) - Seneca Globe (NASDAQ:PCYC) - September 27 at 11:19 AM
News IconAbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica - Yahoo News (NASDAQ:PCYC) - September 27 at 11:19 AM logoAbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma (NASDAQ:PCYC) - September 26 at 6:47 PM logoAbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for - PR Newswire (press release) (NASDAQ:PCYC) - September 26 at 11:30 AM logoSeveral Companies Reach 52-Week Highs - Yahoo Finance (NASDAQ:PCYC) - September 21 at 6:19 PM logoSeveral Companies Reach 52-Week Highs (NASDAQ:PCYC) - September 20 at 11:58 AM
News IconMy "Early Warning" System for Maximum Tech Profits - Money Morning (NASDAQ:PCYC) - August 29 at 6:30 PM logoGoldman Sachs Talks Pfizer's Acquisition Deal Of Medivation - Benzinga (NASDAQ:PCYC) - August 24 at 9:50 AM
News IconJanssen receives Health Canada approval for Imbruvica to treat chronic lymphocytic leukaemia - (NASDAQ:PCYC) - July 23 at 6:15 PM
News IconHealth Canada Approves IMBRUVICA® (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia - Edmonton Journal (NASDAQ:PCYC) - July 20 at 9:38 AM
News IconPharmacyclics' Leukemia Drug Scores over Glaxo's in Head-to-Head Trial - The Westside Story (NASDAQ:PCYC) - June 27 at 6:45 PM
News IconHere's How Julius Caesar Would've Reacted to This Biotech Foul-Up - Money Morning (NASDAQ:PCYC) - June 7 at 6:57 PM
News IconDrug-Makers Once Again Win Street Race- AbbVie Inc. (NYSE:ABBV), Pfizer Inc. (NYSE:PFE) - Seneca Globe (NASDAQ:PCYC) - June 7 at 6:57 PM logoACADIA Pharmaceuticals Could Be Acquired - Seeking Alpha (NASDAQ:PCYC) - June 7 at 9:30 AM logoAbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLL - (NASDAQ:PCYC) - June 6 at 10:26 AM logoAbbVie (ABBV) Receives EC Approval of IMBRUVICA as CLL Treatment - (NASDAQ:PCYC) - May 31 at 7:01 PM logoEuropean Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic ... - PR Newswire (press release) (NASDAQ:PCYC) - May 31 at 6:38 AM
News IconAbbVie Announces FDA Expands Label for Imbruvica - Drug Discovery & Development (NASDAQ:PCYC) - May 16 at 10:11 AM logoMedivation Is for Sale: How Much Should It Get? (NASDAQ:PCYC) - May 13 at 6:07 PM logoWhy June Could Be a Big Month for AbbVie Investors (NASDAQ:PCYC) - May 12 at 4:40 PM
News IconU.S. FDA Expands IMBRUVICA Label To Include Overall Survival Data (NASDAQ:PCYC) - May 11 at 3:46 AM logoAbbVie (ABBV) Announces FDA Update to IMBRUVICA Prescribing Info; Incldues Phase 3 Data for CLL - (NASDAQ:PCYC) - May 9 at 5:29 PM
News IconEMA recommends expanded indication of Janssen's Imbruvica in previously untreated CLL - (NASDAQ:PCYC) - May 2 at 5:51 PM


What is Pharmacyclics' stock symbol?

Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC."

How do I buy Pharmacyclics stock?

Shares of Pharmacyclics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pharmacyclics stock cost?

One share of Pharmacyclics stock can currently be purchased for approximately $257.10.

Pharmacyclics (NASDAQ:PCYC) Chart for Tuesday, February, 21, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Pharmacyclics (NASDAQ:PCYC)

Earnings History Chart

Earnings by Quarter for Pharmacyclics (NASDAQ:PCYC)

Dividend History Chart

Dividend Payments by Quarter for Pharmacyclics (NASDAQ:PCYC)

Last Updated on 2/21/2017 by Staff